Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up

Documenti analoghi

• Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
  di: Martini A, et al.
  Pubblicazione: (2011-09-01)
• National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
  di: Bibalo, C, et al.
  Pubblicazione: (2011)
• The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
  di: Caorsi, Roberta, et al.
  Pubblicazione: (2013)
• An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
  di: Salugina, Svetlana O, et al.
  Pubblicazione: (2014)
• Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
  di: Bader-Meunier, B, et al.
  Pubblicazione: (2011)